Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Cost of Revenue: 2021-2025

Historic Cost of Revenue for Ascendis Pharma A (ASND) over the last 4 years, with Sep 2025 value amounting to $26.1 million.

  • Ascendis Pharma A's Cost of Revenue rose 112.44% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.1 million, marking a year-over-year increase of 76.83%. This contributed to the annual value of $47.9 million for FY2024, which is 0.28% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Cost of Revenue of $26.1 million as of Q3 2025, which was down 26.59% from $35.6 million recorded in Q2 2025.
  • Ascendis Pharma A's Cost of Revenue's 5-year high stood at $35.6 million during Q2 2025, with a 5-year trough of $1.2 million in Q2 2022.
  • For the 3-year period, Ascendis Pharma A's Cost of Revenue averaged around $16.0 million, with its median value being $14.1 million (2023).
  • As far as peak fluctuations go, Ascendis Pharma A's Cost of Revenue soared by 1,114.91% in 2023, and later dropped by 28.42% in 2024.
  • Ascendis Pharma A's Cost of Revenue (Quarterly) stood at $4.0 million in 2021, then climbed by 29.38% to $5.2 million in 2022, then spiked by 301.47% to $20.9 million in 2023, then declined by 28.42% to $15.0 million in 2024, then spiked by 112.44% to $26.1 million in 2025.
  • Its Cost of Revenue was $26.1 million in Q3 2025, compared to $35.6 million in Q2 2025 and $18.4 million in Q1 2025.